Jorge Gómez

Oncogenic Driver Persistence in Liquid Biopsies As Predictor Outcomes in TKI Treated Non-Small Cell Lung Cancer

Rodrigo Paredes, Roberto Borea, Jorge Gómez, Giovanni Nigita et autres

Introduction: Liquid biopsy enables longitudinal assessment of clonal evolution in non-small cell lung cancer (NSCLC). The clinical significance of serial changes in oncogenic driver and tumor suppressor (TS) mutations during tyrosine kinase inhibitor, TKI, therapy remains unclear.

us (code pays fourni par la source)

Antibody drugs conjugates in small-cell lung cancer: present-day status and promises

Arjun Syal, May‐Lucie Meyer, Kenneth Angelino, Noah Osei et autres

INTRODUCTION: Small-cell lung cancer (SCLC) accounts for 15% of lung cancers and is characterized by an aggressive disease course and historically poor prognosis. Although tumors in most patients respond to initial chemotherapy, relapse is nearly universal and treatment options remain limited. Antibody-drug …

us, ch (code pays fourni par la source)

Antibody drugs conjugates in non–small cell lung cancer: current status and challenges

Arjun Syal, May‐Lucie Meyer, Kenneth Angelino, Noah Osei et autres

BACKGROUND: Antibody-drug conjugates (ADCs) are an emerging class of therapeutics that combine the specificity of monoclonal antibodies with cytotoxic or immune-stimulatory payloads. In non-small cell lung cancer (NSCLC), they offer a novel strategy with potential in both first-line therapy and in cases …

us, ch (code pays fourni par la source)

Long term side effects after volumetric modulated arc therapy to the pleura in patients with malignant pleural mesothelioma

V.A. Dumane, Juliana Runnels, Raja M. Flores, Andrea Wolf et autres

us (code pays fourni par la source)

Comparative Analysis of Driver Mutations, Cancer Stage, and Metastatic Burden in Patients with Lung Adenocarcinoma with Prism Compared to COPD and Normal Lung Function

T. GOTO, Roger Paredes, Jorge Gómez, David Steiger

Abstract Rationale: Preserved Ratio Impaired Spirometry (PRISm) is a condition defined by an FEV1 < 80% predicted and FEV1/FVC ratio ≥ 0.7. While specific driver mutations, such as EGFR and ALK1,2, are well-documented in lung adenocarcinoma patients with chronic obstructive pulmonary disease …

us (code pays fourni par la source)

Lung Function Status as a Prognostic Indicator in Adenocarcinoma Survival: A Comparative Analysis of COPD, PRISm, and Normal Lung Function

T. GOTO, Roger Paredes, Jorge Gómez, David Steiger

Abstract Rationale: Preserved Ratio Impaired Spirometry (PRISm), defined by an FEV1 < 80% predicted and FEV1/FVC ratio ≥ 0.7, is an important prognostic factor in lung cancer. While smoking is strongly linked to the occurrence and prognosis of small cell and squamous …

us (code pays fourni par la source)

Evaluation and Management of Lung and Bronchus Cancer

Jorge Gómez

Abstract CT106: A phase 1b/2 trial of dupilumab given in conjunction with PD-1 or PD-L1 blockade and anakinra in the treatment of relapsed/refractory metastatic NSCLC

J. Lowy, Matthew D. Park, Nicholas Rohs, Pamela Vaiskauskas et autres

Abstract Introduction: Chronic inflammation can contribute to growth and immune evasion of solid tumors, with multiple cytokines and chemokines implicated in this process. We previously showed that disrupting the Th2 immune response systemically by blocking IL-4 signaling can activate dendritic cells and …

us (code pays fourni par la source)

PP01.20 Predictive Utility of Circulating Tumor DNA in First- Line Osimertinib Therapy for EGFR-Mutant Metastatic Lung Adenocarcinoma

Rodrigo Paredes, T. GOTO, Shira Litchman, Jorge Gómez et autres

us (code pays fourni par la source)

114P: Feasibility of electronic patient-reported outcomes (ePRO) assessment using a mobile app to monitor patients with advanced ALK+ NSCLC (ePROtector study)

Diego Enrico, Patricio Levit, Jorge Gómez, Federico Waisberg et autres

ar, se (code pays fourni par la source)

Circulating tumor DNA mutations as markers for brain metastases at diagnosis and during treatment

Rodrigo Paredes, T. GOTO, Shira Litchman, Jorge Gómez et autres

Introduction: Brain metastasis is a common complication in non-small cell lung cancer (NSCLC), often associated with distinct genetic patterns. Although next-generation sequencing (NGS) of cerebrospinal fluid (CSF) has been used as an early diagnostic tool for brain metastasis, it is still invasive. …

us (code pays fourni par la source)

Mediastinal lymph node metastases from prostate cancer: Enhanced diagnostic accuracy of PET/CT with 18F-DCFPyL versus 18F-choline

Ricardo Miguel Angulo Amorese, Francisco José Pena Pardo, Jorge Gómez, Nuria Gutiérrez Ruiz et autres

es (code pays fourni par la source)